Alpha-Galactosidase için Bloating and Intestinal Gas
B Kanıt Bunu büyük ölçüde tutarlı sonuçlarla en az bir randomize çalışma desteklemektedir.Reduces gas symptoms from high-fiber foods containing raffinose/stachyose by 50-70%. Beano (alpha-galactosidase 300 GalU) is the most studied formulation.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dalpha\u002Dgalactosidase\u0026condition\u003Dbloating\u002Dand\u002Dgas';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
Sonuç
Reduces gas symptoms from high-fiber foods containing raffinose/stachyose by 50-70%. Beano (alpha-galactosidase 300 GalU) is the most studied formulation.
Key Study Findings
Review
Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review.
Dose: None
vs: None
Outcome: None
Etki: None
None
Popülasyon: None
Randomized Controlled Trial
Double-blind
A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α-galactosidase on gastrointestinal …
Dose: 1200 G
vs: placebo
Outcome: every 30 min during 7
Etki: None
None
Popülasyon: patients with ibs after three standardized
Other
n=17
FABry Disease Patient-Reported Outcome-GastroIntestinal (FABPRO-GI): A new Fabry disease-specific gastrointestinal outcomes instrument.
Dose: None
vs: no treatment
Outcome: None
Etki: None
None
Popülasyon: fabry disease but are often nonspecific
Randomized Controlled Trial
n=31
2.0 weeks
Double-blind
Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment.
Dose: 300 GALU or 150 GALU
vs: Placebo (glucose)
Outcome: GI symptom severity on VAS
Etki: None
pP0.006
Popülasyon: IBS patients (Rome III, H2 producers)
Randomized Controlled Trial
n=125
4 weeks
Double-blind
Does oral α-galactosidase relieve irritable bowel symptoms?
Dose: alpha-galactosidase 600 GalU per meal
vs: placebo
Outcome: overall IBS symptom relief
Etki: no significant difference vs placebo
>0.05
Popülasyon: IBS patients
Case Reports
A family with various symptomatology suggestive of Anderson-Fabry disease and a genetic polymorphism of alpha …
Dose: 3.7nmol/mL/h
vs: None
Outcome: None
Etki: None
None
Popülasyon: patients
Key Statistics
4
Çalışmalar
300
Katılımcılar
↑
Positive
B
Derece
Referenced Papers
International journal of …
2021
16 atıf
Quality of life …
2021
14 atıf
Neurogastroenterology and motility
2021
4 atıf
The American journal …
2018
49 atıf
Scandinavian journal of …
2016
17 atıf
Clinical biochemistry
2015
18 atıf
BMC gastroenterology
2013
12 atıf
Digestive diseases and …
2007
45 atıf
Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.
Other
Molecular genetics and …
2005
84 atıf
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Yaygın Kullanılan Dozajlar
- general:
- 150-300 GalU (alpha-galactosidase units) per serving of gas-producing foods
- standardbeanodose:
- 300 GalU (2-3 tablets) with first bite of problem food
Üst sınır: No established upper limit; adjust per meal as needed
Araştırmalarda İncelenen Dozajlar
| Dozaj | Süre | Etki | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| 1200 G | -- | Neutral | -- |
| None | -- | Positive | 17 |
| 300 GALU or 150 GALU | 2.0 weeks | Positive | 31 |
| alpha-galactosidase 600 GalU per meal | 4 weeks | Neutral | 125 |
| 3.7nmol/mL/h | -- | Mixed | -- |
| None | 2 weeks | Positive | -- |
| 300 or 1200 GalU | -- | Positive | 8 |
En iyi alım zamanı: With the first bite of gas-producing food
Safety & Side Effects
Bildirilen Yan Etkiler
- ⚠ Generally very well-tolerated
- ⚠ Rare allergic reactions to mold-derived enzyme (Aspergillus source)
- ⚠ May cause mild GI discomfort in rare cases
Bilinen Etkileşimler
- ● Acarbose (alpha-galactosidase may counteract the blood sugar-lowering mechanism of acarbose; contraindicated for concurrent use)
- ● Miglitol (similar mechanism conflict as acarbose)
Tolere edilebilir üst alım: No established upper limit; adjust per meal as needed
Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.
Frequently Asked Questions
Does Alpha-Galactosidase help with Bloating and Intestinal Gas?
Based on 4 studies with 300 participants, there is moderate evidence from clinical studies that Alpha-Galactosidase may support Bloating and Intestinal Gas management. Our evidence grade is B (Good Evidence).
How much Alpha-Galactosidase should I take for Bloating and Intestinal Gas?
Studies have used various dosages. A commonly studied range is 150-300 GalU (alpha-galactosidase units) per serving of gas-producing foods. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Alpha-Galactosidase?
Reported side effects may include Generally very well-tolerated, Rare allergic reactions to mold-derived enzyme (Aspergillus source), May cause mild GI discomfort in rare cases. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Alpha-Galactosidase and Bloating and Intestinal Gas?
We rate the evidence as Grade B (Good Evidence). This rating is based on 4 peer-reviewed studies with 300 total participants. The overall direction of effect is positive.
Related Evidence
Şu durum için diğer içerikler: Bloating and Intestinal Gas
Alpha-Galactosidase diğer sağlık durumları için
References
- [1] Fabio Caputo et al.. Int J Environ Res Public Health. 2021. Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review. doi:10.3390/ijerph18063320 PubMed
- [2] Alan L Shields et al.. Qual Life Res. 2021. FABry Disease Patient-Reported Outcome-GastroIntestinal (FABPRO-GI): A new Fabry disease-specific gastrointestinal outcomes instrument. doi:10.1007/s11136-021-02847-9 PubMed
- [3] Lena Böhn et al.. Neurogastroenterol Motil. 2021. A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α-galactosidase on gastrointestinal symptoms in irritable bowel syndrome … doi:10.1111/nmo.14094 PubMed
- [4] C J Tuck et al.. Am J Gastroenterol. 2018. Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment. doi:10.1038/ajg.2017.245 PubMed
- [5] Markku Hillilä et al.. Scand J Gastroenterol. 2016. Does oral α-galactosidase relieve irritable bowel symptoms? doi:10.3109/00365521.2015.1063156 PubMed
- [6] Antonino Tuttolomondo et al.. Clin Biochem. 2015. A family with various symptomatology suggestive of Anderson-Fabry disease and a genetic polymorphism of alpha galactosidase A gene. doi:10.1016/j.clinbiochem.2014.09.018 PubMed
- [7] Giovanni Di Nardo et al.. BMC Gastroenterol. 2013. Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial. doi:10.1186/1471-230X-13-142 PubMed
- [8] Michele Di Stefano et al.. Dig Dis Sci. 2007. The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms. doi:10.1007/s10620-006-9296-9 PubMed
- [9] Maryam Banikazemi et al.. Mol Genet Metab. 2005. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. doi:10.1016/j.ymgme.2005.04.009 PubMed
- [10] T G Ganiats et al.. J Fam Pract. 1994. Does Beano prevent gas? A double-blind crossover study of oral alpha-galactosidase to treat dietary oligosaccharide intolerance. PubMed
FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.